Machine-learning Algorithm to Differentiate Intraoperative Ketamine Dosing Based on Electroencephalographic Density Spectrum Array Analysis

Taipei Veterans General Hospital

Status: Enrolling

Conditions: Multimodal General Anesthesia; Ketamine; Electroencephalographic Density Spectrum Array Analysis; Density Spectrum Array

Treatments: Drug: Ketamine

Study type: Observational

Funder types: Other

Identifiers

NCT05256264

2021-09-008BC

Details and patient eligibility

About

Ketamine is widely used in the setting of multimodal general anesthesia, and the Electroencephalographic density spectral array (DSA) monitoring has been implemented in the practice of anesthesia. The purpose of this study is to investigate the dose-response EEG changes in patients during the perioperative period when ketamine is used. With the application of machine-learning algorithm, we aim to interpret the ketamine dosing precisely and accurately, based on the DSA obtained.

Full description

In this single-blinded randomized controlled trial, we enroll 90 patients undergoing major spine surgery, and candidates are divided into 3 groups: A (control group using sevoflurane only), B (sevoflurane + 3µg/kg ketamine infusion), C (sevoflurane + 6µg/kg/min ketamine infusion). Throughout the perioperative period, under standardized perioperative care, each patient will be monitored with EEG DSA. The data obtained will be utilized for machine-learning in the development of a algorithm to interpret the precise dosing of ketamine in respect of its effect on the EEG DSA. This study is also anticipated to boost the development of dose-response algorithm of other agents, promoting the advancement of the concept of "multimodal general anesthesia"

Enrollment: 90 estimated patients

Sex: All

Ages: 20 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Patients undergoing elective spine surgery
2. Aged 20-80 years old

Exclusion criteria

1. Pregnancy

2. Presence of major brain disorders: stroke, epilepsy, Parkinson's disease, etc.

3. Any of the following major organ disorders:

   1. Chronic pulmonary disease (Clinically diagnosed severe chronic obstructive pulmonary disease or FEV1/FVC <70% or FEV1 <50%)
   2. Heart failure (NYHA III or IV)
   3. Chronic renal failure (eGFR<60ml/min/1.73m2)

4. Ongoing sepsis or infection

5. Ongoing of history of CNS-acting medications/substances use (e.g.: sedatives, hypnotics, stimulants, etc.)

Trial design

90 participants in 3 patient groups

Control group

Description:

Sevoflurane

Low dose ketamine group

Description:

Sevoflurane + 3µg/kg/min ketamine infusion

Treatment:

Drug: Ketamine

High dose ketamine group

Description:

Sevoflurane + 6µg/kg/min ketamine infusion

Treatment:

Drug: Ketamine